Iva B.
- Country
- Croatia
- Department
- Dermatovenerology
Research Overview
- Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adults with Bullous Pemphigoid: An Open-label Extension Study
- Efficacy and Safety Evaluation of Rezpegaldesleukin in Biologic-Naive Adults with Moderate-to-Severe Atopic Dermatitis: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial
- Efficacy and Safety Evaluation of Efgartigimod PH20 SC in Adults with Bullous Pemphigoid: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 68 of 166 partner sites.
Specializations
Dermatological Conditions
This investigator specializes in treating severe dermatological autoimmune conditions, with particular focus on bullous pemphigoid and atopic dermatitis. Their research encompasses both adult and pediatric populations.
- Adult Bullous Pemphigoid Management
- Moderate-to-Severe Atopic Dermatitis
- Pediatric Dermatology
Their work includes evaluation of novel therapeutic approaches for achieving sustained disease remission in dermatological conditions.
Autoimmune Disorders
The investigator conducts research in various immunological diseases, focusing on complement pathway inhibition and immune system modulation.
- Immune Thrombocytopenia
- Antiphospholipid Syndrome
- Behçet's Syndrome
- Dermatomyositis
Their research extends to rare autoimmune conditions requiring innovative therapeutic approaches.
Therapeutic Development
The investigator's work involves evaluating novel biological treatments and their applications in various immune-mediated conditions.
- Complement Pathway Inhibitors
- Subcutaneous Immunotherapy
- Long-term Safety Studies
Their research includes assessment of treatment efficacy in both short-term and extended therapeutic applications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.